Disease progression in cardiac morphology and function in heart failure: ATTR cardiac amyloidosis versus hypertensive left ventricular hypertrophy

M. Y. Henein1 · B. Pilebro1 · Per Lindqvist2

Received: 15 December 2021 / Accepted: 25 February 2022 / Published online: 11 March 2022
© The Author(s) 2022

Abstract

Background Transthyretin cardiac amyloidosis (ATTR-CA) is today more frequently recognized but the rate of progression of cardiac dysfunction is not well established. The aim of this study is to investigate the nature of cardiac structure and function changes, over time, in a retrospective cohort of ATTR-CA patients.

Methods Fifty-one patients with ATTR-CA (mean age 78 ± 7 years, 30 females) were compared with 20 patients with heart failure but no amyloidosis (HFnCA) (mean age 76 ± 7 years, 5 females), all with septal thickness ≥ 14 mm. All patients underwent DPD scintigraphy and an echocardiogram (Echo 2) which was compared with a previous echocardiographic examination (Echo 1), performed at least 3 years before.

Results Over the follow-up period, the interventricular septal thickness (IVST) and relative wall thickness (RWT) in ATTR-CA increased from 16 (4) to 18 (5) mm and from 0.51 (0.17) to 0.62 (0.21) respectively, \( p < 0.001 \) for both, by a mean increase of 0.4 mm/year and 0.03 mm/year, \( p = 0.009 \) and \( p = 0.002 \) compared with HFnCA), respectively. RWT > 0.45 (AUC = 0.77) and RELAPS > 2.0 (AUC 0.86) both predicted positive DPD diagnosis for ATTR-CA.

Conclusion In ATTR-CA patients, the overtime-increase in RWT and IVST was worse than that seen in patients with heart failure but no cardiac amyloidosis. Also, RWT and relative apical sparing predicted diagnosis of ATTR-CA, thus could strengthen the use of follow-up echocardiographic findings as red flag for the diagnosis of ATTR-CA.

Keywords Cardiac amyloidosis · Echocardiography · DPD scintigraphy · Prognosis

Introduction

Transthyretin (TTR) amyloidosis (ATTR) is the most common type of systemic amyloidosis and is classified into a hereditary type (ATTRv), and a wild-type transthyretin (ATTRwt) amyloidosis [1, 2]. One of the most common, and fatal manifestations of ATTR is cardiac amyloidosis (CA) [3]. The exact prevalence of ATTR-CA is unknown since it was previously considered a rare condition, but probably more common than presumed. [4–6]. Typical findings that raise the suspicion of ATTR-CA can be obtained from echocardiography, although the definitive diagnosis is always confirmed either by myocardial biopsy or non-invasively using nuclear scintigraphy [7, 8]. Typical echocardiographic findings suggestive of ATTR-CA include increased left ventricular (LV) wall thickness followed by development of restrictive ventricular filling patterns [9] and right heart involvement [10]. Furthermore, decreased global myocardial longitudinal strain (GLS) and increased relative apical sparing (RELAPS) have been reported as cardiac deformation signs associating ATTR-CA [11, 12]. Progression of cardiac amyloidosis is not adequately investigated. Recently, NAC (National Amyloidosis Centre) score including data from NT-proBNP and eGFR predicted clinical outcome in ATTR-CA [13]. Also, recent report by Itzhaki et al. showed that increased wall thickness and restrictive filling pattern...
develop over several years and can be seen prior to final diagnosis in patients with ATTR and AL amyloidosis [14].

The aims of this study were firstly, to investigate the ATTR-CA disease progression using echocardiography and compare it with that of heart failure patients with increased wall thickness but no CA (HFnCA), based on DPD scintigraphy. Secondly, to evaluate echocardiographic predictors for DPD scintigraphy verified ATTR-CA diagnosis.

**Materials and methods**

**Patient population**

This is a retrospective study in patients with heart failure and increased septal thickness. Inclusion criteria for further investigations in the patients were (1) septal thickness $>14$ mm, (2) absence of types of CA other than ATTRwt and ATTRv, and (3) confirmed final diagnosis of ATTR amyloidosis, using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scintigraphy examination. Part of this cohort findings was previously published [15]. We included 35 patients with ATTRv and 16 with ATTRwt from our local database, all diagnosed with ATTR-CA based on positive DPD scintigraphy (grade 2–3). In total, there were 51 ATTR-CA patients met the inclusion criteria for the study. For comparison of disease progression, we compared the ATTR-CA patients with 20 non-cardiac amyloidosis heart failure patients (HFnCA) with left ventricular hypertrophy, all due to primary hypertension, and none had positive DPD scan. Patients diagnosed with hypertrophic cardiomyopathy and aortic stenosis as causes for increased LV wall thickness were excluded from the HFnCA group. All patients and controls had clinical signs of heart failure and septal thickness $>14$ mm on the Echo 2 examination.

Excluding AL amyloidosis in all patients was based on blood and urine analysis of serum free light chain (FLC) abnormalities (Freelite, Binding Site reagent, reference range 0.27–1.64) and the presence of monoclonal bands. Sequencing of the TTR-gene was also undertaken in all patients to diagnose ATTRv amyloidosis. Patients with Perugini score 1 were excluded from the study due to uncertain diagnosis. To evaluate the disease progression rate, we compared the two echocardiograms (Echo 1 and Echo 2) obtained using the same vendor. All patients had had an echocardiogram at the time of the DPD scan (Echo 2) and a previous echo (Echo 1) at least 3 years before.

**Echocardiographic examination**

Echocardiographic examination was performed using a Vivid E9 system (GE Medical Systems, Horten, Norway) equipped with an adult 1.5–4.3 MHz phased array transducer. All Echo 2 studies were performed by the same investigator (PL) blinded to Echo 1 findings. Echo 1 studies were performed by various physiologists at the Clinical Physiology Department, Umeå University. Standard views from the parasternal long axis-, short axis- and apical four-chamber views were used, following conventional protocols. Flow velocities were obtained using pulsed and continuous wave Doppler techniques as proposed by recent guidelines [16, 17]. All acquisitions were made from the left lateral position. Analysis was done blinded to patient’s category, ATTR-CA or HFnCA.

Relative ventricular wall thickness (RWT) was calculated according to the American society of echocardiography (ASE) recommendations (posterior wall thickness $\times 2 / \text{Left ventricular (LV) diastolic diameter (LVDd)}$). Trans-mitral blood flow velocities were obtained with the sample volume placed at the tips of the mitral valve leaflets with optimal angulation to LV inflow. From trans-mitral flow velocities, we measured early (E) diastolic and atrial contraction (A) flow velocities. Retrograde systolic trans-tricuspid flow was obtained from either parasternal right ventricular inflow or apical 4-chamber view, for measuring peak retrograde trans-tricuspid pressure drop using continuous wave Doppler, which reflects pulmonary artery systolic pressures. Left atrial volume was measured using the modified Simpson’s single plan calculation [4 chamber view] [18].Pulsed wave tissue Doppler velocities were also obtained to assess mean LV lateral and septal myocardial early diastolic velocities ($e'$) and E/e' was calculated [18]. All Doppler recordings were made at a sweep speed of 50–100 mm/s with a superimposed ECG (lead II). Off-line analyses were made using commercially available software (General Electric, EchoPac version BT 13, 113.0, Waukesha, Wisconsin, US), and the means of three consecutive cardiac cycles were calculated.

**Assessment of LV deformation function**

Anatomical landmarks were used, and care was taken for echocardiographic image acquisition to ensure adequate LV myocardium tracking, avoiding foreshortening of LV cavity when measuring global LV strain. Longitudinal myocardial deformation was assessed from the two-dimensional echocardiographic acquisitions using speckle tracking technology and was analyzed off-line. From the apical four chamber, two chamber and apical parasternal long axis views the endocardial border detection of the septal, apical and lateral LV walls was made manually, to analyze global LV strain (GLS) measurements. Strain recordings from three cardiac cycles were averaged, to assess GLS which were measured at end-systole with the reference point set at the onset of two consecutive QRS-complexes of the superimposed ECG. RELAPS was also calculated as average apical
strain / (average basal strain + average mid cavity strain). Strain analyses were measured using a dedicated workstation (General Electric, EchoPac version BT 13, 113.0, Waukesha, Wisconsin, US). 2D strain assessment was done based on the recommendations of the European Association of Cardiovascular Imaging [19].

**DPD scintigraphy**

All patients underwent DPD scintigraphy examination using an Infinia Hawkeye hybrid single-photon-emission computed-tomography gamma camera (SPECT-CT) (General Electric Medical Systems, Milwaukee, WI, USA,) with a low-energy high-resolution collimator. An intravenous injection of ~ 750 MBq DPD was given 3 h prior to the acquisition of whole-body planar image, followed by a non-contrast, low dose CT scan and a SPECT acquisition, 60 projections, iteratively reconstructed to a 128×128 matrix (OSEM, 3 iterations, 10 subsets) with scatter and CT-based attenuation correction. Reconstruction of SPECT images was performed on the Xeleris workstation (GE Healthcare, Waukesha, WI, USA). DPD scores were reported by two experienced clinicians using the Perugini’s grading system [20] with grade 0 being negative and grades 1 to 3 increasingly positive.

**Statistics**

Statistical analysis was preformed using SPSS®, version 27 (IBM). Data are presented as mean, standard deviation (SD) if data were normally distributed, maximum and minimum values for continuous variables. Percentages were used to describe categorical variables. Categorical variables were compared using chi-square and McNemar tests, and continuous variables were compared using the Student’s t-tests for normally distributed data or Mann–Whitney U tests for non-normally distributed data. Wilcoxon paired test was used for comparing non-parametric data. Data were presented as median and interquartile range 25–75 for non-normally distributed data. Normality was assessed by Shapiro–Wilk’s test. ROC analysis was performed to evaluate the accuracy (area under the curve) and differentiating groups. P values were presented with a 0.05 level of statistical significance.

**Results**

Patient’s characteristics are presented in Table 1. Fifty-one patients with ATTR-CA (mean age 78 ± 7 years, 30 females) and 20 patients with heart failure (HFnCA) (mean age 76 ± 7, 5 females) were enrolled in the study. All patients had septal thickness ≥ 14 mm. Follow-up time was longer in HFnCA than ATTR-CA patients (p < 0.001). All HFnCA patients had diagnosis of systemic hypertension as the cause for increased LV wall thickness. At the time of DPD, ATTR-CA patients had significantly higher NT-proBNP (p = 0.045), lower diastolic blood pressure (p = 0.046) and weight (p < 0.001), Table 1.

**Disease progression in ATTR-CA and HFnCA**

There was no difference in septal thickness between the two patient groups at the time of Echo 1. At follow up, septal thickness increased significantly in ATTR-CA (p < 0.001) but not in HFnCA. LV posterior wall and relative wall thickness both increased only in ATTR-CA (p < 0.001). Left atrial volume increased in both groups but only significantly in ATTR-CA (p < 0.05). In the same group GLS decreased significantly (p < 0.001). 16% of ATTR-CA had AF at Echo 1 which increased significantly to 55% at the time of Echo 2. In comparison, only one patient with HFnCA had AF at Echo 1 and 12% had AF at Echo 2. The prevalence of AF

---

Image: ROC curve testing relative wall thickness (RWT) and relative apical sparing (RELAPS) at baseline in predicting DPD positive ATTR-CA, RWT; AUC = 0.77, p = 0.002 and RELAPS; AUC = 0.86, p < 0.001

---

**Ethics**

The study complied with the declaration of Helsinki and the study protocol was approved by the Regional Ethics Committee of Umeå (reference numbers: 2016-435-31 M, 2018-418-32 M, 2018-137-32 M) and all subjects gave written informed consent to participate in the study.
At Echo 2, RELAPS did not change over time in either of the two groups, Table 2. At the time of Echo 1, RELAPS was significantly higher ($p < 0.001$) in ATTR-CA than HFnCA. The prevalence of AF was higher in ATTRwt at Echo 1 but lower at Echo 2. However, the prevalence of AF increased in both groups, Table 3.

**Disease progression rate in ATTR-CA and HFnCA**

Since the time difference between Echo 1 and Echo 2 varied between patients, we investigated the rate of progression in echo measurements, such as RWT, RELAPS, GLS, RV-RA retrograde pressure drop and LA volume. We calculated the rate by dividing the difference in these measurements from Echo 1 to Echo 2 by the time difference between the two studies, in years. In ATTR-CA, septal thickness and RWT both increased by 0.39 mm and 0.023 mm/year, respectively, which was significantly faster for both compared with HFnCA ($p=0.009$ and 0.022). There was no difference between groups in the rate of progression of RELAPS, right ventricular-right atrial pressure drop or left atrial volume. The rate of fall of LV GLS was faster in ATTR-CA compared to HFnCA ($p=0.05$).

**Disease progression rate in ATTRwt and ATTRv**

The disease progression in ATTRwt and ATTRv was not different between groups, except for RWT that progressed at Echo 2 was significantly higher ($p<0.001$) in ATTR-CA than HFnCA. RELAPS did not change over time in either of the two groups, Table 2.

---

**Table 1** Clinical data at the time for DPD verified diagnosis

|                  | ATTR-CA ($n = 51$) | HFnCA ($n = 20$) | $P$-value |
|------------------|--------------------|------------------|-----------|
| NT-proBNP log, ng/L | $3.1 \pm 0.6$      | $2.8 \pm 0.6$    | 0.045     |
| Troponin, ng/L    | $31.5 (35)$        | $23 (19)$        | 0.086     |
| SBP, mmHg         | $130 \pm 20$       | $140 \pm 17$     | 0.061     |
| DBP, mmHg         | $78 \pm 10$        | $84 \pm 10$      | 0.046     |
| Height, cm        | $175 \pm 8$        | $175 \pm 9$      | 0.799     |
| Weight, kg        | $78 \pm 13$        | $92 \pm 21$      | <0.001    |
| Female sex (%)    | $30 (59\%)$        | $5 (29\%)$       | 0.017     |
| Follow up time, years | $6 \pm 2$     | $8 \pm 2$        | <0.001   |
| NYHA, 2,3A,3B (%) | –                  | 14/63/21         |           |
| Betablockers, n   | 20                 | 19               |           |
| ACE/ARB, n        | 15                 | 20               |           |
| MRA/Furosemid, n  | 12/12              | 6                |           |
| HFnEF, n          | 38                 | 13               |           |
| HFrEF, n          | 13                 | 6                |           |
| HFrEF, n          | 3                  | 1                |           |

Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressure, ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, MRA mineral corticoid receptor antagonist, HFnEF heart failure with preserved ejection fraction, $mr$ mid range, $r$ = reduced

**Table 2** Echocardiographic data at first and second echo

|                  | ATTR-CA ($n = 51$) | HFnCA ($n = 20$) |
|------------------|--------------------|------------------|
|                  | First echo         | Last echo        | First echo         | Last echo |
| Age, years       | $72 \pm 7$         | $78 \pm 7^{*}$   | $68 \pm 7$         | $76 \pm 7^{**}$ |
| HR, bpm          | $74 (61)$          | $70 (60)$        | $66 (14)$          | $69 (21)$   |
| IVS, mm          | $16 (4)$           | $18 (5)^{***}$   | $16 (3)$           | $16 (4)$    |
| LVDD, mm         | $45 \pm 5$         | $44 \pm 5$       | $51 \pm 9$         | $48 \pm 7$  |
| PWT, mm          | $12 (3)$           | $14 (3)^{***}$   | $10 (2)$           | $11 (5)$    |
| LAV, ml          | $74 (54)$          | $90 (115)^{*}$   | $60 (45)$          | $114 (124)$ |
| RWT, mmHg        | $0.51 (0.17)$      | $0.62 (0.21)^{***}$ | $0.45 (0.17)$      | $0.38 (0.44)$ |
| GLS, %           | $-18.0 \pm 4.8$    | $-13.2 \pm 4.8^*$ | $-13.1 \pm 6.0$    | $-11.1 \pm 2.8$ |
| RV-RA, mmHg      | $26 (8)$           | $25 (15)$        | $24 (3)$           | $27 (31)$   |
| E velocity, cm/s | $73 \pm 25$        | $62 \pm 24$      | $70 \pm 20$        | $62 \pm 23$ |
| RELAPS           | $2.2 \pm 0.6$      | $2.0 \pm 0.9$    | $1.6 \pm 0.5$      | $1.4 \pm 1.6$ |
| AF, %            | $8$                | $27^{*}$         | $1$                | $2$        |

Abbreviations: HR heart rate, IVS interventricular septum, LVDD left ventricular diastolic diameter, PWT posterior wall thickness in diastole, LAV left atrial volume, RWT relative wall thickness, GLS global longitudinal strain, RV right ventricular, RA right atrial, E early diastolic, RELAPS relative apical sparing, AF atrial fibrillation. *$p<0.05$ comparing first echo, **$p<0.001$
faster in ATTvt ($p = 0.012$). Comparing ATTR-CA patients with or without hypertension showed no differences in disease progression rate, Table 4.

### Table 3: Echocardiographic data at first and second echo in ATTRwt and ATTRv

|                      | ATTRwt (n = 16) | ATTRv (n = 35) |                      |                      |
|----------------------|----------------|----------------|----------------------|----------------------|
|                      | First echo     | Last echo      | First echo           | Last echo            |
| Age, years           | 80 ± 5         | 84 ± 6*        | 69 ± 6               | 75 ± 6***            |
| HR, bpm              | 77 ± 19        | 72 ± 12        | 76 ± 12              | 66 ± 13              |
| IVS, mm              | 15 (5)         | 16 (3)*        | 16 (5)               | 20 (7)***            |
| LVDD, mm             | 46 ± 6         | 45 ± 5*        | 45 ± 5               | 43 ± 5               |
| PWT, mm              | 11.5 ± 1.6     | 13.0 ± 1.9*    | 11.9 ± 2.7           | 14.4 ± 3.2*          |
| LAV, ml              | 80 (49)        | 82 (35)        | 50 (30)              | 79 (40)***           |
| RWT, mm              | 0.54 (0.19)    | 0.57 (0.17)*   | 0.51 (0.20)          | 0.65 (0.20)***       |
| GLS, %               | 15 ± 5         | 12 ± 3.0       | 19 ± 4               | 14 ± 3               |
| RELAPS              | 2.2 (0.8)      | 1.3 (0.7)***   | 2.3 (0.4)            | 2.2 (1.0)            |
| AF, (%)              | 5              | 11*            | 2                    | 15***                |
| Female sex (n)       | 2              | 28             |                      |                      |

Abbreviations: HR heart rate, IVS interventricular septum, LVDD left ventricular diastolic diameter, PWT posterior wall thickness in diastole, LAV left atrial volume, RWT relative wall thickness, GLS global longitudinal strain, RV right ventricular, RA right atrial, E early diastolic, RELAPS relative apical sparing, AF atrial fibrillation, *$p < 0.05$ comparing first echo; **$p < 0.005$ comparing first echo.

### Table 4: Progression rate in different patient groups

|                      | ATTR-CA (n = 51) | HFnCA (n = 20) | P-value |
|----------------------|------------------|----------------|---------|
| ΔIVS/year            | 0.39 (0.92)      | 0.25 (0.37)    | 0.009   |
| ΔRWT/year            | 0.023 ± 0.035    | 0.003 ± 0.017  | 0.022   |
| ΔRELAPS/year         | 0.065 (0.17)     | 0.030 (0.27)   | 1.000   |
| ΔGLS/year            | 0.50 (1.3)       | 0.76 (1.2)     | 0.055   |
|                      | ATTRwt (n = 16)  | ATTRv (n = 35) |         |
| ΔIVS/year            | 0.57 ± 0.54      | 0.54 ± 0.51    | 0.844   |
| ΔRWT/year            | 0.008 ± 0.02     | 0.029 ± 0.04   | 0.012   |
| ΔRELAPS/year         | 0.06 ± 0.21      | 0.06 ± 0.18    | 0.878   |
| ΔGLS/year            | 0.34 ± 1.4       | 0.88 ± 0.90    | 0.127   |
|                      | ATTR-CA HT (n = 15) | ATTR-CA nHT (n = 34) | P-value |
| ΔIVS/year            | 0.66 ± 0.62      | 0.52 ± 0.47    | 0.406   |
| ΔRWT/year            | 0.021 ± 0.031    | 0.024 ± 0.038  | 0.831   |
| ΔRELAPS/year         | 0.079 ± 0.20     | 0.061 ± 0.23   | 0.803   |
| ΔGLS/year            | 0.60 ± 1.60      | 0.57 ± 0.78    | 0.363   |

Abbreviations: IVS interventricular septum, RWT relative wall thickness, GLS global longitudinal strain, RELAPS relative apical sparing, HT hypertension

### Discussion

In two groups of heart failure patients with similar LV cavity morphology and wall thickness, our findings show significant differences in the rate of increased wall thickness changes over time, according to objective evidence for the presence of ATTR. Patients with ATTR-CA had faster rate of increased septal and relative wall thickness compared with HFnCA due to systemic hypertension. In the same group of patients with ATTR-CA, LV myocardial strain showed significant fall, more than that seen in HFnCA. Our findings also show a potential impact of the two types of ATTR-CA, with the wild type patients being older, frequently males, with larger left atrium and have faster rate of increased relative wall thickness compared to the non-amyloid. Hypertension in ATTR-CA did not seem to influence progression rate in cardiac function and morphology. Finally, RWT and RELAPS with a similar accuracy predicted the presence of ATTR-CA on the DPD scan.

It is well known that increased myocardial thickness is a common finding in patients with heart failure and preserved...
LVEF because of the increased prevalence of long-standing hypertension in these patients [21]. Recent studies have shown that cardiac amyloidosis is another common [22] cause of increased wall thickness in those patients, which when confirmed should be expected to influence treatment strategy [23]. We and others have reported a number of measures which assist in differentiating the two conditions of benign myocardial hypertrophy and infiltration as a causes for increased wall thickness [24]. Firstly, hypertension and obesity are more common findings in HFpEF than in ATTR-CA. Secondly, higher NT-proBNP is a common feature of ATTR-CA compared with HFnCA [25]. In this study, concentrically increased LV wall thickness (increased RWT) and relative apical sparing were more common in ATTR-CA compared with HFnCA. Interestingly, similar findings were found in our patients, up to 11 years before DPD verified diagnosis, with increased RWT and RELAPS predicting DPD diagnosis of ATTR-CA. A further detailed assessment of the pattern of increase of wall thickness showed that septal LV segments demonstrated faster progression rate of their thickness in ATTR-CA compared to HFnCA which was not paralleled in cardiac function measures (measured as GLS and RELAPS). This finding was independent of the type of ATTR-CA, ATTRwt or ATTRv. The same pattern of increase in septal thickness was significantly slower in HFnCA, a finding that might have significant implications in patient’s management.

The increase in wall thickness in our two heart failure groups of patients is fundamentally different. While the benign increase in wall thickness due to hypertension is caused by cellular hypertrophy and myocyte disarray, that in cardiac amyloidosis is mainly due to extra cellular amyloid deposition. The latter has been reported to be less pronounced in AL amyloidosis [26] but has more aggressive rate of progression which itself is known to carry prognostic value in AL amyloidosis patients [27]. The left atrium behaved differently in the two conditions, with its volume increasing more in ATTR-CA. The more pronounced increase in left atrial volume in ATTR-CA and especially in ATTRwt, is most likely related to the higher prevalence of atrial fibrillation in this group.

Clinical implications

Our results show that both RWT and RELAPS could predict DPD-scintigraphy based diagnosis of ATTR-CA, a finding that has significant clinical relevance. It indicates the significant potential and importance of echocardiographic measurements in the diagnosis of ATTR-CA, with high accuracy, thus supporting its clinical role as red flag for ATTR cardiac amyloidosis. However, this potential relationship is limited since 12 of the ATTR-CA patients had septal thickness < 14 mm at baseline. Therefore, the proposed measures need to be re-tested in a larger cohort of patients. The unique application of RWT as an imaging marker for disease should be praised for being simple, universally available and does not need sophisticated expensive techniques. Its accuracy is also not dependent on rhythm patterns, as is the case with other investigations. In addition, a reduction in RWT and LV wall thickness and improved GLS has been found in ATTRv patients treated with RNA interference therapy [28] which strengthens the importance of assessing wall thickness and LV deformation pattern in ATTR-CA patients.

Limitations: The main limitation of this study is the relatively small sample volume; hence findings should be reproduced in a larger cohort before been considered for clinical guidance. The presence of atrial fibrillation could have influenced the results, especially those of LV function. We did not adjust for treatment, medical or liver transplantation, in either of the two patient groups which could have an influence on the results. However, we considered DPD verified evidence for ATTR cardiac amyloidosis an important differentiating evaluation of the disease progress.

Conclusion

In ATTR-CA patients, the overtime increase in septal thickness was more profound than that seen in patients with heart failure but no cardiac amyloidosis. Also, relative wall thickness and relative apical sparing predicted diagnosis of ATTR-CA, thus could be considered as early echocardiographic markers for ATTR-CA. However, these findings need to be revalidated in a larger group of ATTR-CA.

Funding Open access funding provided by Umea University. The study was supported by The Swedish Heart and Lung foundation, grants no 20160787 and 20200160 and The Swedish Research Council grant no 2019–01338.

Declarations

Conflict of interest Per Lindqvist had consultancy agreement with Pfizer.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Maleszewski JJ (2015) Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol 24(6):343–350
2. Falk RH (2005) Diagnosis and management of the cardiac amyloidoses. Circulation 112(13):2047–2060
3. Falk RH, Dubrey SW (2010) Amyloid heart disease. Prog Cardiovasc Dis 52(4):347–361
4. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36(38):2585–2594
5. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L (2008) Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 40(3):232–239
6. Mohamed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispensieri A, Zeldenrust SR, Redfield MM (2014) Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2(2):113–122
7. Hafeez AS, Bavry AA (2020) Diagnosis of transthyretin amyloid cardiomyopathy. Cardio Thor 9(1):85–95
8. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispensieri A, Wechalekar AD, Berk JL, Quarta CC, Mital P, Lachmann HJ, Bokhari S, Castano A, Durbala S, Johnson GB, Glaudemans AW, Rezk TF, Fontana M, Palladini G, Milan P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24):2404–2412
9. Garcia-Pavia P, Raperze C, Adler Y, Arad M, Basso C, Brucato A, Burazco I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A (2021) Diagnosis and treatment of cardiac amyloidosis. A position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur J of Heart Fail. 42(16):1554–1568
10. Arvidsson S, Henein MY, Wikstrom G, Suhr OB, Lindqvist P (2018) Right ventricular involvement in transthyretin amyloidosis. Amyloid 25(3):160–166
11. Aljaroudi WA, Desai MY, Tang WH, Phelan D, Cerqueira MD, Jaber WA (2014) Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol 21(2):271–283
12. Jurcut R, Onciul S, Adam R, Stan C, Coria D, Raperze C, Popescu BA (2020) Multiparametric imaging in cardiac amyloidosis: a primer for cardiologists. Eur Heart J Cardiovasc Imaging 21(8):833–844
13. Day JK, Duncan GW, Khoo TK, Williams-Gray CH, Breen DP, Barker RA, Burn DJ, Lawson RA, Yarnall AJ (2020) Progression of neuropsychiatric symptoms over time in an incident Parkinson’s disease cohort (ICICLE-PD). Brain Sci 10(2):78
14. Itzhaki Ben Zadok O, Eisien A, Shapira Y, Monakier D, Iacobishvili Z, Schwartzengruber S, Abelov A, Ofek H, Kazum S, Ben-Avraham B, Hamdan A, Bentald T, Sage A, Kornowski R, Vaturi M (2020) Natural history and disease progression of early cardiac amyloidosis evaluated by echocardiography. Am J Cardiol 133:126–133
15. Lindmark K, Pilereb B, Sundstrom T, Lindqvist P (2020) Prevalence of wild type transthyretin cardiac amyloidosis in a heart failure clinic. ESC Heart Fail 8(1):745–749
16. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA (2002) Doppler quantification task force of the n, standards committee of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 15(2):167–184
17. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellicka PA, Picard MH, Roman MJ, Seward J, Shaverse WS, Solomon DS, Spencer KT, Sutton MS, Stewart WJ (2005) Chamber quantification Writing G, American Society of Echocardiography, its Standards, European Association of E. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18(12):1440–1463.
18. Mitter SS, Shah SJ, Thomas JD (2017) A test in context: E/A and E/e’ to assess diastolic dysfunction and LV filling pressure. J Am Coll Cardiol 69(11):1451–1464
19. Galderisi M, Cosyns B, Edvardsen T, Cardin N, Delgado V, Di Salvo G, Donal E, Sade LE, Erande L, Garbi M, Grapsa J, Hagnordorff A, Kamp O, Magne J, Santoro C, Stefanidis A, Lencellotti P, Popescu B, Habib G (2017) Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 18(12):1301–1310
20. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Raperze C (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphonate 1.2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46(6):1076–1084
21. Lekavich CL, Barksdale DJ, Neelon V, Wu JR (2015) Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review. Heart Fail Rev 20(6):643–653
22. Klaasssen RH, van Veldhuisen DJ, Nihusius H, van den Berg MP, Hazenberg BP, van den Meer P (2020) Cardiac transthyretin-derived amyloidosis: an emerging target in heart failure with preserved ejection fraction? Card Fail Rev 6:21
23. Oghina S, Bouguenin W, Bezd M, Kharoubi M, Komajda M, Cohen-Solal A, Mebazaa A, Damy T, Bodez D (2021) The impact of patients with cardiac amyloidosis in HFPEF trials. JACC Heart failure 9(3):169–178
24. Gustavsson S, Gransan G, Gronlund C, Wiklund U, Morner S, Henein M, Suhr OB, Lindqvist P (2015) Can echocardiography and ECG discriminate hereditary transthyretin V30M amyloidosis from hypertrophic cardiomyopathy? Amyloid 22(3):163–170
25. Kyrkou P, Mouselimis D, Tsarouchas A, Rigopoulos A, Bakogiannis C, Noutsias M, Vassilkos V (2018) Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers. BMC Cardiovasc Disord 18(1):221
26. Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, Gagliardi C, Milandri A, Rapezzi C, Falk RH (2014) Left ventricular involvement in transthyretin amyloidosis. Circulation 129(18):1840–1849
27. Kristen AV, Perz JB, Schonland SO, Hansen A, Hegernhart U, Sack FU, Goldschmidt H, Katus HA, Dengler TJ (2007) Rapid progression of left ventricular wall thickness predicts mortality
in cardiac light-chain amyloidosis. J Heart Lung Transplant 26(12):1313–1319

28. Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH 3rd, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O (2019) Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 139(4):431–443

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.